

Michael D Wiese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3954484/publications.pdf>

Version: 2024-02-01

137
papers

4,674
citations

117625

34
h-index

110387

64
g-index

138
all docs

138
docs citations

138
times ranked

6479
citing authors

#	ARTICLE	IF	CITATIONS
1	Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs. <i>Rheumatology</i> , 2023, 62, 583-595.	1.9	3
2	Global View on Ant Venom Allergy: from Allergenic Components to Clinical Management. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 123-144.	6.5	7
3	Population Pharmacokinetic Model for Tramadol and O-desmethyltramadol in Older Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022, 47, 387-402.	1.6	1
4	Association between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab. <i>Bladder Cancer</i> , 2022, 8, 81-88.	0.4	2
5	Maternal-placental-fetal drug metabolism is altered by late gestation undernutrition in the pregnant ewe. <i>Life Sciences</i> , 2022, 298, 120521.	4.3	3
6	Quantitation of methotrexate polyglutamates in human whole blood, erythrocytes and leukocytes collected via venepuncture and volumetric absorptive micro-sampling: a green LC-MS/MS-based method. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 6029-6046.	3.7	6
7	Therapeutic Potential of a Novel Vitamin D3 Oxime Analogue, VD1-6, with CYP24A1 Enzyme Inhibitory Activity and Negligible Vitamin D Receptor Binding. <i>Biomolecules</i> , 2022, 12, 960.	4.0	5
8	Reframe the pain: Divided attention and positive memory reframing to reduce needle pain and distress in children—A feasibility randomized controlled trial. <i>European Journal of Pain</i> , 2022, 26, 1702-1722.	2.8	5
9	Precision Medicine With Leflunomide: Consideration of the <i>DHODH</i> Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 983-989.	3.4	8
10	Alterations in drug disposition in older adults: a focus on geriatric syndromes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 41-52.	3.3	33
11	Opioid prescribing and risk of drug-opioid interactions in older discharged patients with polypharmacy in Australia. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 365-374.	2.1	7
12	COVID-19: can we treat the mother without harming her baby?. <i>Journal of Developmental Origins of Health and Disease</i> , 2021, , 1-11.	1.4	4
13	Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post hoc multicohort analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110090.	2.7	3
14	Impact of resveratrol-mediated increase in uterine artery blood flow on fetal haemodynamics, blood pressure and oxygenation in sheep. <i>Experimental Physiology</i> , 2021, 106, 1166-1180.	2.0	6
15	The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data. <i>Npj Breast Cancer</i> , 2021, 7, 30.	5.2	22
16	Population pharmacokinetic model of subcutaneous fentanyl in older acute care patients. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1357-1368.	1.9	2
17	LC-MS/MS analysis of vitamin D3 metabolites in human serum using a salting-out based liquid-liquid extraction and DAPTAD derivatization. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1173, 122654.	2.3	10
18	Efficacy and safety of statins in ethnic differences: a lesson for application in Indigenous Australian patient care. <i>Pharmacogenomics</i> , 2021, 22, 553-571.	1.3	0

#	ARTICLE	IF	CITATIONS
19	The efficacy of systemic administration of lipopolysaccharide in modelling pre-motor Parkinson's disease in C57BL/6 mice. <i>NeuroToxicology</i> , 2021, 85, 254-264.	3.0	8
20	Simultaneous LC-MS/MS quantification of oxycodone, tramadol and fentanyl and their metabolites (noroxycodone, oxymorphone, O- desmethyltramadol, N- desmethyltramadol, and norfentanyl) in human plasma and whole blood collected via venepuncture and volumetric absorptive micro sampling. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 203, 114171.	2.8	7
21	Redox ratio in the left ventricle of the growth restricted fetus is positively correlated with cardiac output. <i>Journal of Biophotonics</i> , 2021, 14, e202100157.	2.3	9
22	Impact of maternal late gestation undernutrition on surfactant maturation, pulmonary blood flow and oxygen delivery measured by magnetic resonance imaging in the sheep fetus. <i>Journal of Physiology</i> , 2021, 599, 4705-4724.	2.9	4
23	A review of liquid biopsy as a tool to assess epigenetic, cfDNA and miRNA variability as methotrexate response predictors in patients with rheumatoid arthritis. <i>Pharmacological Research</i> , 2021, 173, 105887.	7.1	14
24	Intrauterine growth restriction alters the activity of drug metabolising enzymes in the maternal-placental-fetal unit. <i>Life Sciences</i> , 2021, 285, 120016.	4.3	6
25	Hepatic cytochrome P450 function is reduced by life-long Western diet consumption in guinea pig independent of birth weight. <i>Life Sciences</i> , 2021, 287, 120133.	4.3	4
26	Predicting Thrombocytopenia in Patients With Breast Cancer Treated With Ado-trastuzumab Emtansine. <i>Clinical Breast Cancer</i> , 2020, 20, e220-e228.	2.4	10
27	Repeat serological testing for anti-citrullinated peptide antibody after commencement of therapy is not helpful in patients with seronegative rheumatoid arthritis. <i>Internal Medicine Journal</i> , 2020, 50, 818-822.	0.8	3
28	The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data. <i>Frontiers in Oncology</i> , 2020, 10, 1130.	2.8	10
29	The impact of intrauterine growth restriction on cytochrome P450 enzyme expression and activity. <i>Placenta</i> , 2020, 99, 50-62.	1.5	3
30	Development of a method to determine cytochrome P450 1A2, 2C9, 2D6 and 3A4 activity sheep hepatic microsomes. <i>Journal of Pharmacological and Toxicological Methods</i> , 2020, 106, 106934.	0.7	5
31	Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. <i>Scientific Reports</i> , 2020, 10, 18634.	3.3	15
32	Nuances to precision dosing strategies of targeted cancer medicines. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00625.	2.4	9
33	Methamphetamine administration increases hepatic CYP1A2 but not CYP3A4 activity in female guinea pigs. <i>PLoS ONE</i> , 2020, 15, e0233010.	2.5	9
34	Fetal cardiovascular response to acute hypoxia during maternal anesthesia. <i>Physiological Reports</i> , 2020, 8, e14365.	1.7	10
35	A literature review of treatment-specific clinical prediction models in patients with breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102908.	4.4	10
36	Prevalence and Factors Associated with Analgesic Prescribing in Poly-Medicated Elderly Patients. <i>Drugs and Aging</i> , 2020, 37, 291-300.	2.7	12

#	ARTICLE	IF	CITATIONS
37	Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opinion on Investigational Drugs, 2020, 29, 475-482.	4.1	36
38	Considerations in selecting postoperative analgesia for pregnant sheep following fetal instrumentation surgery. Animal Frontiers, 2019, 9, 60-67.	1.7	27
39	Subcutaneous maternal resveratrol treatment increases uterine artery blood flow in the pregnant ewe and increases fetal but not cardiac growth. Journal of Physiology, 2019, 597, 5063-5077.	2.9	23
40	Factors associated with medication adherence in a longitudinal study of rheumatoid arthritis patients. International Journal of Clinical Practice, 2019, 73, e13375.	1.7	17
41	Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy. Journal of Pharmaceutical and Biomedical Analysis, 2019, 172, 1-8.	2.8	7
42	Does poor fetal growth influence the extent of fetal exposure to maternal medications?. Pharmacological Research, 2018, 130, 74-84.	7.1	10
43	Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. British Journal of Clinical Pharmacology, 2018, 84, 462-476.	2.4	53
44	Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 205-210.	0.7	5
45	Towards complete identification of allergens in Jack Jumper (<i>Myrmecia pilosula</i>) ant venom and their clinical relevance: An immunoproteomic approach. Clinical and Experimental Allergy, 2018, 48, 1222-1234.	2.9	13
46	Intrauterine growth restriction may reduce hepatic drug metabolism in the early neonatal period. Pharmacological Research, 2018, 134, 68-78.	7.1	15
47	The <i>PTPN22</i> gene is associated with idiopathic inflammatory myopathy. Muscle and Nerve, 2017, 55, 270-273.	2.2	3
48	Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users. Rheumatology International, 2017, 37, 897-904.	3.0	23
49	The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?. Pharmaceutical Research, 2017, 34, 1544-1550.	3.5	15
50	Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies. AAPS Journal, 2017, 19, 1136-1147.	4.4	26
51	Putting recommendations into practice: Australian rheumatologists'™ opinions on leflunomide use in rheumatoid arthritis. Clinical Rheumatology, 2017, 36, 791-798.	2.2	2
52	Clinical Outcomes Associated with Medication Regimen Complexity in Older People: A Systematic Review. Journal of the American Geriatrics Society, 2017, 65, 747-753.	2.6	142
53	Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis. International Journal of Rheumatic Diseases, 2017, 20, 576-583.	1.9	7
54	Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study. Therapeutic Advances in Musculoskeletal Disease, 2017, 9, 213-229.	2.7	30

#	ARTICLE	IF	CITATIONS
55	Disease activity trajectories in early rheumatoid arthritis following intensive ^{DMARD} therapy over 3 years: association with persistence to therapy. International Journal of Rheumatic Diseases, 2017, 20, 1447-1456.	1.9	12
56	Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. British Journal of Cancer, 2017, 117, 913-920.	6.4	145
57	Factors influencing the quality of <i>Myrmecia pilosula</i> (Jack Jumper) ant venom for use in in vitro and in vivo diagnoses of allergen sensitization and in allergen immunotherapy. Clinical and Experimental Allergy, 2017, 47, 1478-1490.	2.9	6
58	Intracellular CD3 ⁺ T Lymphocyte Teriflunomide Concentration Is Poorly Correlated with and Has Greater Variability Than Unbound Plasma Teriflunomide Concentration. Drug Metabolism and Disposition, 2017, 45, 8-16.	3.3	9
59	Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide. International Journal of Rheumatic Diseases, 2017, 20, 1795-1797.	1.9	1
60	Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 31-49.	3.3	52
61	Treating rheumatoid arthritis to target: physician and patient adherence issues in contemporary rheumatoid arthritis therapy. Journal of Evaluation in Clinical Practice, 2017, 23, 486-493.	1.8	17
62	Improving community access to terminal phase medicines in Australia: identification of the key considerations for the implementation of a "core medicines list". Australian Journal of Primary Health, 2017, 23, 373.	0.9	4
63	Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia. Medical Journal of Australia, 2016, 204, 64-68.	1.7	14
64	A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity. British Journal of Clinical Pharmacology, 2016, 81, 1046-1057.	2.4	1
65	Extended boiling of peanut progressively reduces IgE allergenicity while retaining T cell reactivity. Clinical and Experimental Allergy, 2016, 46, 1004-1014.	2.9	37
66	Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?. International Journal of Clinical Practice, 2016, 70, 340-350.	1.7	2
67	<i>PTPN22</i> R620W minor allele is a genetic risk factor for giant cell arteritis. RMD Open, 2016, 2, e000246.	3.8	9
68	Genetic polymorphism of <i>CYP1A2</i> but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. British Journal of Clinical Pharmacology, 2016, 81, 113-123.	2.4	19
69	Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort. Journal of Rheumatology, 2016, 43, 1643-1649.	2.0	11
70	Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis. Pharmacogenomics, 2016, 17, 1725-1732.	1.3	15
71	Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. European Journal of Cancer, 2016, 55, 122-130.	2.8	32
72	Medication Regimen Complexity and Polypharmacy as Factors Associated With All-Cause Mortality in Older People. Annals of Pharmacotherapy, 2016, 50, 89-95.	1.9	95

#	ARTICLE	IF	CITATIONS
73	Medication Regimen Complexity and Number of Medications as Factors Associated With Unplanned Hospitalizations in Older People: A Population-based Cohort Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 831-837.	3.6	63
74	Targeted pharmacotherapy after somatic cancer mutation screening. <i>F1000Research</i> , 2016, 5, 1551.	1.6	12
75	Clinical translation of predictive markers for anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer. <i>Translational Cancer Research</i> , 2016, 5, S31-S34.	1.0	1
76	Targeted pharmacotherapy after somatic cancer mutation screening. <i>F1000Research</i> , 2016, 5, 1551.	1.6	6
77	Response to Physiologically Based Pharmacokinetic Model for Prediction of Leflunomide and Teriflunomide—Should Consideration Be Given to Cannalicular Efflux Transporters?. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 564-564.	2.5	0
78	Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 362-371.	2.5	15
79	Pharmacists in Australian general practice: an opportunity for expertise in precision medicine. <i>Therapeutic Advances in Drug Safety</i> , 2015, 6, 186-188.	2.4	14
80	Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2015, 112, 1888-1894.	6.4	272
81	Alterations in drug disposition in older adults. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 491-508.	3.3	91
82	The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies—a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 411-423.	1.9	23
83	Pilosulins: A review of the structure and mode of action of venom peptides from an Australian ant <i>Myrmecia pilosula</i> . <i>Toxicon</i> , 2015, 98, 54-61.	1.6	36
84	Factors associated with medication regimen complexity in older people: a cross-sectional population-based study. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1099-1108.	1.9	34
85	A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 777-788.	2.4	4
86	Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years. <i>Arthritis Research and Therapy</i> , 2015, 17, 48.	3.5	24
87	Reply: Comment on “Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer”™. <i>British Journal of Cancer</i> , 2015, 113, 1635-1635.	6.4	127
88	Feasibility of a Patient-Centered Deprescribing Process to Reduce Inappropriate Use of Proton Pump Inhibitors. <i>Annals of Pharmacotherapy</i> , 2015, 49, 29-38.	1.9	65
89	Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. <i>Annals of Oncology</i> , 2015, 26, 13-21.	1.2	439
90	BRAF V600E and survival benefit of anti-EGFR monoclonal antibody (mAb) therapy for metastatic colorectal cancer (mCRC): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, e14605-e14605.	1.6	0

#	ARTICLE	IF	CITATIONS
91	The benefits and harms of deprescribing. Medical Journal of Australia, 2014, 201, 386-389.	1.7	72
92	<i>CYP2C19</i> Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated With Clopidogrel. Circulation: Cardiovascular Genetics, 2014, 7, 895-902.	5.1	107
93	Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes. Therapeutic Advances in Drug Safety, 2014, 5, 62-66.	2.4	8
94	Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. Pharmacogenomics Journal, 2014, 14, 350-355.	2.0	25
95	Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. British Journal of Clinical Pharmacology, 2014, 78, 738-747.	2.4	246
96	Individualization of leflunomide dosing in rheumatoid arthritis patients. Personalized Medicine, 2014, 11, 449-461.	1.5	6
97	Benefits of deprescribing on patients' adherence to medications. International Journal of Clinical Pharmacy, 2014, 36, 26-29.	2.1	77
98	The rheumatoid arthritis susceptibility polymorphism <i>PTPN22</i> C1858T is not associated with leflunomide response or toxicity. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 555-560.	1.5	7
99	Metabolic and safety issues for multiple sclerosis pharmacotherapy – opportunities for personalised medicine. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1145-1159.	3.3	3
100	Cost-effectiveness of genotyping to guide treatment. Pharmacogenomics, 2014, 15, 727-729.	1.3	6
101	Immediate-type hypersensitivity drug reactions. British Journal of Clinical Pharmacology, 2014, 78, 1-13.	2.4	44
102	Polypharmacy and Medication Regimen Complexity as Factors Associated with Hospital Discharge Destination Among Older People: A Prospective Cohort Study. Drugs and Aging, 2014, 31, 623-630.	2.7	38
103	Medication Regimen Complexity and Unplanned Hospital Readmissions in Older People. Annals of Pharmacotherapy, 2014, 48, 1120-1128.	1.9	60
104	Systemic allergy to EDTA in local anesthetic and radiocontrast media. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 225-229.e1.	3.8	24
105	Development and validation of the patients' attitudes towards deprescribing (PATD) questionnaire. International Journal of Clinical Pharmacy, 2013, 35, 51-56.	2.1	85
106	Patient Barriers to and Enablers of Deprescribing: a Systematic Review. Drugs and Aging, 2013, 30, 793-807.	2.7	364
107	Review of the Cost Effectiveness of Pharmacogenetic-Guided Treatment of Hypercholesterolaemia. Pharmacoeconomics, 2013, 31, 377-391.	3.3	15
108	Leflunomide for Inflammatory Arthritis in End-Stage Renal Disease on Peritoneal Dialysis: A Pharmacokinetic and Pharmacogenetic Study. Annals of Pharmacotherapy, 2013, 47, e15-e15.	1.9	15

#	ARTICLE	IF	CITATIONS
109	Predicted metabolic drug clearance with increasing adult age. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1019-1028.	2.4	43
110	Challenges and Limitations in the Interpretation of Systematic Reviews: Making Sense of Clopidogrel and CYP2C19 Pharmacogenetics. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 376-382.	4.7	22
111	Multidose drug dispensing and optimising drug use in older people. <i>Age and Ageing</i> , 2013, 42, 556-558.	1.6	14
112	Costâ€effectiveness of using <i>CYP2C19</i> genotype to guide selection of clopidogrel or ticagrelor in Australia. <i>Pharmacogenomics</i> , 2013, 14, 2013-2021.	1.3	33
113	The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 496-502.	1.9	57
114	People's Attitudes, Beliefs, and Experiences Regarding Polypharmacy and Willingness to Deprescribe. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 1508-1514.	2.6	182
115	Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1025-1035.	3.3	40
116	Association of <i>DHODH</i> haplotype variants and response to leflunomide treatment in rheumatoid arthritis. <i>Pharmacogenomics</i> , 2012, 13, 1427-1434.	1.3	24
117	Adherence to medication for the treatment of psychosis: rates and risk factors in an Ethiopian population. <i>BMC Clinical Pharmacology</i> , 2012, 12, 10.	2.5	21
118	Ultrarush versus semirush initiation of insect venom immunotherapy: AÂrandomized controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 162-168.	2.9	44
119	Difficulties Reducing Inappropriate Prescribing of Proton Pump Inhibitors in the Elderly. <i>Drugs and Aging</i> , 2012, 29, 925-926.	2.7	4
120	Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2012, 14, R163.	3.5	41
121	Perceived and actual paracetamol dosing inÂoverweight and obese children. <i>European Journal of Hospital Pharmacy</i> , 2012, 19, 438-442.	1.1	3
122	Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding. <i>Thrombosis and Haemostasis</i> , 2012, 108, 199-200.	3.4	18
123	Oral drug challenges in nonâ€steroidal antiâ€inflammatory drugâ€induced urticaria, angioedema and anaphylaxis. <i>Internal Medicine Journal</i> , 2012, 42, 665-671.	0.8	33
124	Causes of ant sting anaphylaxis in Australia: the Australian Ant Venom Allergy Study. <i>Medical Journal of Australia</i> , 2011, 195, 69-73.	1.7	36
125	Using Time-Resolved Fluorescence to Measure Serum Venom-Specific IgE and IgG. <i>PLoS ONE</i> , 2011, 6, e16741.	2.5	9
126	Stability of <i>Myrmecia pilosula</i> (Jack Jumper) Ant venom for use in immunotherapy. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 54, 303-310.	2.8	12

#	ARTICLE	IF	CITATIONS
127	Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 325-331.	2.8	39
128	Myrmecia pilosula (Jack Jumper) ant venom: Validation of a procedure to standardise an allergy vaccine. Journal of Pharmaceutical and Biomedical Analysis, 2008, 46, 58-65.	2.8	18
129	Pilosulin 5, a novel histamine-releasing peptide of the Australian ant, Myrmecia pilosula (Jack Jumper) Tj ETQq1 1 0.784314 rgBT /Over 3.0 52	3.0	52
130	Original article: Myrmecia pilosula (Jack Jumper) ant venom: identification of allergens and revised nomenclature. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 437-443.	5.7	46
131	Proteomic analysis of Myrmecia pilosula (jack jumper) ant venom. Toxicon, 2006, 47, 208-217.	1.6	41
132	Efficacy of ant venom immunotherapy and whole body extracts. Journal of Allergy and Clinical Immunology, 2005, 116, 464-465.	2.9	7
133	Characterisation of major peptides in "jack jumper" ant venom by mass spectrometry. Toxicon, 2004, 43, 173-183.	1.6	57
134	Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet, The, 2003, 361, 1001-1006.	13.7	129
135	Raised INR with Concurrent Warfarin and Azithromycin. Journal of Pharmacy Practice and Research, 1999, 29, 159-161.	0.2	8
136	Unexpected Orthostatic Hypotension with Venlafaxine. Journal of Pharmacy Practice and Research, 1999, 29, 215-216.	0.2	2
137	The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients. Nephrology Dialysis Transplantation, 1999, 14, 2047-2049.	0.7	21